{"filing":{"accession_number":"0001829126-26-009999","cik":"0001479419","ticker":"KALA","company_name":"KALA BIO, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-03","primary_document":"kalabio_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/kalabio_8k.htm"},"events":[{"id":32749,"run_id":30109,"accession_number":"0001829126-26-009999","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kala entered into an Exclusive Distribution and Reseller Agreement with Virotek on September 3, 2026, appointing Kala as the sole and exclusive distributor of a genetic testing and screening program for ophthalmology in the United States for five years. While this is a material commercial partnership with defined revenue-sharing terms (50/50 net profit split), right of first refusal on related products, and conditional exclusivity tied to a milestone, it does not constitute a merger, acquisition, or change of control (ma_activity), nor does it fit other specific financial or governance categories. This is a material operational/strategic partnership that would affect investor assessment of the company's growth prospects and revenue streams.","company_name":"KALA BIO, Inc.","ticker":"KALA","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":36002,"accession_number":"0001829126-26-009999","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kala entered into an Exclusive Distribution and Reseller Agreement with Virotek on September 3, 2026, appointing Kala as the sole and exclusive distributor of a genetic testing and screening program for ophthalmology in the United States for five years. While this is a material commercial partnership with defined revenue-sharing terms (50/50 net profit split), right of first refusal on related products, and conditional exclusivity tied to a milestone, it does not constitute a merger, acquisition, or change of control (ma_activity), nor does it fit other specific financial or governance categories. This is a material operational/strategic partnership that would affect investor assessment of the company's growth prospects and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:25:37.418040+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36002,"accession_number":"0001829126-26-009999","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kala entered into an Exclusive Distribution and Reseller Agreement with Virotek on September 3, 2026, appointing Kala as the sole and exclusive distributor of a genetic testing and screening program for ophthalmology in the United States for five years. While this is a material commercial partnership with defined revenue-sharing terms (50/50 net profit split), right of first refusal on related products, and conditional exclusivity tied to a milestone, it does not constitute a merger, acquisition, or change of control (ma_activity), nor does it fit other specific financial or governance categories. This is a material operational/strategic partnership that would affect investor assessment of the company's growth prospects and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:25:37.418040+00:00","company_name":"KALA BIO, Inc.","ticker":"KALA","filing_date":"2026-09-10"}]}